

Important Notice: LabPMM is not enrolled in the Medicare program and is unable to bill Medicare (or Medicare supplemental insurance) for any laboratory tests, including those that meet the Medicare criteria set forth in the "Laboratory Date of Service for Clinical Laboratory and Pathology Specimens" regulation (42 CFR Section 414.510(b)(5).

By submitting this Test Requisition Form, the ordering entity represents and warrants that the specimen is not for a Medicare patient and acknowledges and agrees that LabPMM will not refund any payment made to LabPMM in the event the entity submits a Medicare patient specimen in error.

Received Date:								
Time: Tech:				Place patient label here if desired				
Specimen Volume:								
Tube/Container:								
Accession #:								
PATIENT INFORMATION *REQUIRED INFORMATION				PHYSICIAN/CLIENT INFORMATION *REQUIRED INFORMATION				
Name*:				Physician*:				
Date of Birth*:				Institution*:				
Reported Ancestry:					Address*: Medicare #:			
Medical Record #:		Gender:	М	F	F Address 2:			
GENE PANEL REQUESTED				Phone*:	Phone*: Fax:			
MyAML® Acute Myeloid Leukemia Sequence analysis of 194 genes					Email:	Email:		
ABCC1, ACVR2B, ADRBK1, AKAP13, ANKRD24, ARID2, ARID4B, ASXL1, ASXL2, ASXL3, BCOR, BCORL1, BRINP3, BRPF1, BUB1, CACNA1E, CBL, CBX5, CBX7, CDC73, CEBPA, CEP164, CPNE3, CSF1R, CSTF2, TCTCF, CYLD, DCLK1, DDX1, DDX23, DHX32,				SPECIMEN TYPE				
DIS3, DNAH9, DNMT1, DNMT3A, DNMT3B, DYRK4, EED, EGFR, EP300, EPHA2, EPHA3, ETV3, EZHZ, FANCC, FLT3, GA GATA2, GFI, GLI, HDAC2, HDAC3, HNRNPK, HRAS, IDH1, IDH2, IZEF1, JAK1, JAK2, JAK3, JMJDIC, KDM2B, KDM3B, KDM KDM6B, KIT, KMT2B, KMT2C, KRAS, MAPK1, METTL3, MST1R, MTA2, MTOR, MXRA5, MYB, MYC, MYLK2, MYO3A, NF NOTCH1, NOTCH2, NPM1, NRAS, NRK, OBSCN, PAPD5, PAX5, PDGFRA, PDGFRA, PDGSB, PDSS, PDSS, PNSC, PKDL12, PLR POUR2A, PRDM16, PRBM9, PRKCG, PRFP3, PRPFADB, PRPRB, PTR, PTPN11, PTPN14, PTPRT, RAD21, RBBPA, RBMX, RPS6KA6, SAP130, SCML2, SETBP1, SETD2, SF1, SF3A1, SF3B1, SMC1A, SMC3, SMC5, SMG1, SNRNP200, SOS1, SPEN, SRRM2, SRSF2, SRSF6, STAG2, STK323, STK33, STK36, SUDS3, SUMO2, SUDFSH, SUZIZ, CTC4, TT-1, TET2, THB8, TPS TRA2B, TRIO, TTBK1, TYK2, TYW1, U2AF1, U2AF1, U2AF2, UBA3, WAC, WAPAL, WEE1, WNK3, WNK4, WT1, ZBTB33, ZB' ZRSR2   ABL1, ADGRG7, AFF1, BCR, CBBF, CREBBP, DEK, EIFA£2, ELL, ETV6, GAS6, GAS7, KAT6A, KAT6B, KMT2A, ME COM, MKL1, MLLT10, MLLT1, MLLT3, MLLT4, MYH11, NSD1, NUP214, NUP98, PICALM, PML , RARA, RBM15, RPN1, RUN RUNXIT1, SEPT5, SET, TFG, TMEM255B  MYMRD® NGS precision hotspot panel to detect and track myeloid malignancies of 23 genes			M3B, KDM6A, YO3A, NF1, DIL2, PLRG1, 4, RBMX, S1, SPEN, HRB, TP53, TB33, ZBTB7B, MT2A, ME- PPN1, RUNX1,	Peripheral Blood  2-4 mL in EDTA or Sodium Heparin  Bone Marrow  1-2 mL in EDTA or Sodium Heparin  Isolated DNA  1-2 µg from EDTA or Sodium Heparin	Transport specimens ambient (18-25°C/64-77°F) or with cold packs in provided packaging. If using cold packs for transport, make sure cold pack is not indirect contact with specimen. Do not freeze. Specimens should arrive in the laboratory within 48 hours of collection.			
ASKLI, BRAF, CALR, CEBPA, CSF3R, DNMT3A, FLT3, IDH1, IDH2, JAK2, KIT, KMT2A, KRAS, MPL, MYH11, NRAS, NPM1, PTPN11, RUNX1, SF3B1, SRSF2, TP53, ZRSR2					T 2 µg nom EBWYor occurrence	'		
SAMPLE INFORMATION								
WBC count:				-	liagnosis:			
Tumor %:					Code:			
				n for Submission:				
Has the patient received an Allogenic Stem Cell Transplantation: Yes No								
Please send all pathology and test results from all other molecular diagnostic assays.								
LabPMM® may use your leftover specimen and your health information, including genetic information, in an anonymized, or de-identified, form (unless otherwise allowed by applicable law) for research and education purposes. Such uses may result in the development of commercial products and services. You will not receive notice of any specific uses and you will not receive any compensation for these uses. All such uses will be in compliance with applicable law. You may refuse to allow LabPMM® to use your leftover specimen or information for research by marking the applicable box below. You may also withdraw your consent for research uses at a later date by submitting an "Opt-Out of Research Form" to the laboratory.								
Opt Out of Research	pt Out of Research Patient Signature:				Date:			
LabPMM® PATIENT INFORMED CONSENT								
I, the patient, certify to having the assay performed, acknowledge that:								
I understand that this test is voluntary and I have had the opportunity to ask questions and discuss with my healthcare provider the risks, benefits and alternatives of this test. I have been informed about the availability of genetic counseling and have been provided with information identifying an appropriate healthcare provider from whom I might obtain such counseling. I have read and understand the content of this document and may have a copy if desired. These test results may impact life, disability, and long-term care insurance. I understand that my sample will be tested for many different genes that may have conditions that impact me and my blood relatives. The American College of Medical Genetics and Genomics (ACMG) suggests that secondary findings be discussed with those who share these variants with me. I have considered the way to communicate this information to them.								
Patient Signature:								